Compare Citius Pharmaceuticals Inc (CTXR) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KraneShares Hang Seng TECH Index ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while KraneShares Hang Seng TECH Index ETF trades at $13.35. The key difference: KraneShares Hang Seng TECH Index ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | KTEC | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $19.51 |
52-Week Low | $0.53 | $12.00 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
KTEC trades at $12.90, down 1.07% with mixed technical signals showing bullish moving averages but overbought RSI conditions. The stock faces consolidation near key support/resistance at $13. Fundamental data remains limited pending updated financial disclosures from recent SEC filings.
The technical setup suggests near-term consolidation while awaiting fundamental catalysts. Investment opportunity depends on upcoming earnings validation, though limited institutional coverage and thin financial data increase reliance on technical momentum for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
